Status:
COMPLETED
SPP100 Dose Finding Study in Japan
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
20-80 years
Phase:
PHASE2
Brief Summary
This study will evaluate the efficacy of SPP100 in lowering blood pressure in patients with essential hypertension.
Eligibility Criteria
Inclusion
- Mild to moderate essential hypertension
- Age: ≥20 years old and \<80 years old (at time informed consent obtained)
- Sex: N/A
- Admission status: Outpatient
Exclusion
- Pregnant women, lactating women, potentially pregnant women, or women who wish to become pregnant
- Patients having a mean sitting diastolic blood pressure of ≥110 mmHg and/or a mean sitting systolic blood pressure of ≥180 mmHg at either Visit 2 or 3
- Patients with secondary hypertension as a complication or patients suspected of having secondary hypertension(due to aortic coarctation, primary aldosteronism, coarctation of renal artery, renal hypertension
- Patients suspected of having malignant hypertension
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2005
Estimated Enrollment :
445 Patients enrolled
Trial Details
Trial ID
NCT00311012
Start Date
August 1 2004
End Date
March 1 2005
Last Update
November 8 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Tokyo, Japan